Subscribe to RSS
Download PDF
DOI: 10.1055/s-0043-1775568
ABO Blood Group and the Risk of Thrombosis in Cancer Patients: A Mini-Review
Abstract
Cancer-associated thrombosis (CT), especially venous thromboembolism (VTE), is a common occurrence with several factors contributing to a wide diversity in thrombosis risk. The association between ABO blood groups and the risk for CT has been examined in various studies, with non-O blood type associated with an increased thrombosis risk; however, these studies have reported varying results with recognized limitations. ABO blood groups are known to be implicated in hemostasis, in an association mediated through von Willebrand factor (VWF). In this narrative review, we aim to summarize the current knowledge surrounding the role of ABO blood groups in VTE, with a particular focus on the role of VWF and other contributing risk factors on VTE occurrence. We found evidence from literature for the impact of ABO blood groups in determining the risk of VTE in healthy populations, with a limited number of studies examining this effect in cancer patients. Additionally, research on the impact of ABO on different cancer types lacks rigor, particularly in regard to other risk factors. Overall, most studies showed strong association of increased risk of VTE amongst cancer patients with non-O blood groups and increased VWF levels. This association was weaker in a few studies. Further research is needed before a solid conclusion can be made about the ABO or ABO-VWF-mediated hypercoagulability and VTE risk in various cancers. These studies will help determine if ABO typing can be an added biomarker to improve VTE risk assessment models in cancer patients.
Publication History
Article published online:
26 September 2023
© 2023. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Fernandes CJ, Morinaga LTK, Alves Jr JL. et al. Cancer-associated thrombosis: the when, how and why. Eur Respir Rev 2019; 28 (151) 180119
- 2 Abdol Razak NB, Jones G, Bhandari M, Berndt MC, Metharom P. Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment. Cancers (Basel) 2018; 10 (10) 380
- 3 Mulder FI, Horváth-Puhó E, van Es N. et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood 2021; 137 (14) 1959-1969
- 4 Hisada Y, Garratt KB, Maqsood A. et al. Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer. Blood Adv 2021; 5 (02) 487-495
- 5 Heit JA, O'Fallon WM, Petterson TM. et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002; 162 (11) 1245-1248
- 6 Grover SP, Hisada YM, Kasthuri RS, Reeves BN, Mackman N. Cancer therapy-associated thrombosis. Arterioscler Thromb Vasc Biol 2021; 41 (04) 1291-1305
- 7 Daguenet E, Maison M, Tinquaut F. et al. Venous thromboembolism and radiation therapy: the final radiation-induced thrombosis study analysis. Cancer Med 2022; 11 (08) 1753-1762
- 8
Franchini M,
Favaloro EJ,
Targher G,
Lippi G.
ABO blood group, hypercoagulability, and cardiovascular and cancer risk. Crit Rev
Clin Lab Sci 2012; 49 (04) 137-149
MissingFormLabel
- 9 Englisch C, Moik F, Nopp S, Raderer M, Pabinger I, Ay C. ABO blood group type and risk of venous thromboembolism in patients with cancer. Blood Adv 2022; 6 (24) 6274-6281
- 10 Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111 (10) 4902-4907
- 11 Moik F, Englisch C, Pabinger I, Ay C. Risk assessment models of cancer-associated thrombosis - potentials and perspectives. Thromb Update 2021; 5: 100075
- 12 Syrigos K, Grapsa D, Sangare R. et al. Prospective assessment of clinical risk factors and biomarkers of hypercoagulability for the identification of patients with lung adenocarcinoma at risk for cancer-associated thrombosis: the observational ROADMAP-CAT study. Oncologist 2018; 23 (11) 1372-1381
- 13 Spyropoulos AC, Eldredge JB, Anand LN. et al. External validation of a venous thromboembolic risk score for cancer outpatients with solid tumors: the COMPASS-CAT venous thromboembolism risk assessment model. Oncologist 2020; 25 (07) e1083-e1090
- 14 Cartron JP, Rouger P. eds. Molecular Basis of Human Blood Group Antigens (Blood Cell Biochemistry, 6). New York, NY: Plenum; 1995
- 15 Yamamoto F, McNeill PD, Hakomori S. Human histo-blood group A2 transferase coded by A2 allele, one of the A subtypes, is characterized by a single base deletion in the coding sequence, which results in an additional domain at the carboxyl terminal. Biochem Biophys Res Commun 1992; 187 (01) 366-374
- 16
Ward SE,
O'Sullivan JM,
O'Donnell JS.
The relationship between ABO blood group, von Willebrand factor, and primary hemostasis.
Blood 2020; 136 (25) 2864-2874
MissingFormLabel
- 17 Ibrahim-Kosta M, Bailly P, Silvy M. et al. ABO blood group, glycosyltransferase activity and risk of venous thromboembolism. Thromb Res 2020; 193: 31-35
- 18 Pépin M, Kleinjan A, Hajage D. et al. ADAMTS-13 and von Willebrand factor predict venous thromboembolism in patients with cancer. J Thromb Haemost 2016; 14 (02) 306-315
- 19
James PD,
Connell NT,
Ameer B.
et al.
ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood
Adv 2021; 5 (01) 280-300
MissingFormLabel
- 20 Smith NL, Rice KM, Bovill EG. et al. Genetic variation associated with plasma von Willebrand factor levels and the risk of incident venous thrombosis. Blood 2011; 117 (22) 6007-6011
- 21 Franchini M, Frattini F, Crestani S, Bonfanti C, Lippi G. von Willebrand factor and cancer: a renewed interest. Thromb Res 2013; 131 (04) 290-292
- 22 Terraube V, Pendu R, Baruch D. et al. Increased metastatic potential of tumor cells in von Willebrand factor-deficient mice. J Thromb Haemost 2006; 4 (03) 519-526
- 23 Mannucci PM, Karimi M, Mosalaei A, Canciani MT, Peyvandi F. Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease). Haematologica 2003; 88 (04) 454-458
- 24 Böhm M, Gerlach R, Beecken WD, Scheuer T, Stier-Brück I, Scharrer I. ADAMTS-13 activity in patients with brain and prostate tumors is mildly reduced, but not correlated to stage of malignancy and metastasis. Thromb Res 2003; 111 (1–2): 33-37
- 25 Regierer AC, Kuehnhardt D, Schulz CO. et al. Breast cancer-associated thrombotic microangiopathy. Breast Care (Basel) 2011; 6 (06) 441-445
- 26 Liu X, Chen X, Yang J, Guo R. Association of ABO blood groups with von Willebrand factor, factor VIII and ADAMTS-13 in patients with lung cancer. Oncol Lett 2017; 14 (03) 3787-3794
- 27 Gran OV, Brækkan SK, Hansen JB. Prothrombotic genotypes and risk of venous thromboembolism in cancer. Thromb Res 2018; 164 (Suppl. 01) S12-S18
- 28 Li D, Pise MN, Overman MJ. et al. ABO non-O type as a risk factor for thrombosis in patients with pancreatic cancer. Cancer Med 2015; 4 (11) 1651-1658
- 29 Urabe F, Kimura S, Iwatani K. et al. The impact of ABO blood type on developing venous thromboembolism in cancer patients: systematic review and meta-analysis. J Clin Med 2021; 10 (16) 3692
- 30 Setiawan B, Permatadewi CO, de Samakto B. et al. Von Willebrand factor:antigen and ADAMTS-13 level, but not soluble P-selectin, are risk factors for the first asymptomatic deep vein thrombosis in cancer patients undergoing chemotherapy. Thromb J 2020; 18 (01) 33
- 31 Wang G, Wang H, Shen Y. et al. Association between ABO blood group and venous thrombosis related to the peripherally inserted central catheters in cancer patients. J Vasc Access 2021; 22 (04) 590-596
- 32 Turan D, Yasar HA, Aksu OB. et al. Risk factors for thrombosis risk in patients with cancer. J Oncol Sci 2018; 4 (03) 130-133